Status:
UNKNOWN
Bortezomib and Dexamethasone in Treating Patients With Multiple Myeloma That Has Relapsed or Has Not Responded to Treatment
Lead Sponsor:
Sparrow Regional Cancer Center
Conditions:
Multiple Myeloma and Plasma Cell Neoplasm
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer. Drugs used in chemotherapy, such as dexametha...
Detailed Description
OBJECTIVES: Primary * Determine the overall response rate (complete response and partial response) in patients with relapsed or refractory multiple myeloma treated with induction therapy and mainten...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Diagnosis of multiple myeloma
- Refractory or relapsed disease meeting the following criteria:
- Primary refractory disease and first-line relapsing disease
- Progressive disease after last therapy
- PATIENT CHARACTERISTICS:
- ECOG performance status 0-2
- Life expectancy \> 3 months
- Platelet count ≥ 50,000/mm³ (≥ 30,000/mm³ for patients with significant bone marrow involvement)
- Transfusions allowed
- Hemoglobin ≥ 7.5 g/dL
- Absolute neutrophil count ≥ 750/mm³
- Serum calcium \< 14 mg/dL
- AST and ALT \< 2.5 times upper limit of normal
- Creatinine clearance ≥ 30 mL/min
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- No peripheral neuropathy ≥ grade 2 within the past 14 days
- No hypersensitivity to boron or mannitol
- No cardiovascular complications, including any of the following:
- Myocardial infarction within the past 6 months
- New York Heart Association class III-IV heart failure
- Uncontrolled angina
- Ventricular arrhythmias
- Electrocardiographic evidence of acute ischemia or active conduction system abnormalities
- Cardiac amyloidosis
- No other cancer or treatment for cancer other than basal cell cancer of the skin within the past 5 years
- No poorly controlled chronic diseases (e.g., diabetes mellitus or hypertension)
- No HIV positivity
- No hepatitis B surface antigen or active hepatitis C infection
- No active systemic infection requiring therapy
- No serious medical or psychiatric illness that would interfere with study participation
- PRIOR CONCURRENT THERAPY:
- No plasmapheresis within the past 4 weeks
- No major surgery within the past 4 weeks
- No prior bortezomib
- No chemotherapy (e.g., clarithromycin) within the past 4 weeks
- No radiotherapy within the past 3 weeks
- No corticosteroids (\> 10 mg/day of prednisone or equivalent) within the past 3 weeks
- No other immunotherapy within the past 8 weeks
- No other investigational drugs within the past 14 days
- No concurrent participation in other clinical research studies
Exclusion
Key Trial Info
Start Date :
March 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00389701
Start Date
March 1 2006
Last Update
January 10 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sparrow Regional Cancer Center
Lansing, Michigan, United States, 48909-7980